AIM ImmunoTech is a biopharmaceutical company based in Riverton, NJ, dedicated to developing innovative immunotherapy solutions for a wide range of debilitating and life-threatening conditions. Their lead program, Ampligen, is an immuno-modulator that has demonstrated broad spectrum activity in preclinical studies and is currently being evaluated in clinical trials for various diseases, including oncology, immune disorders, and viral diseases.
With a focus on improving patients' lives, AIM ImmunoTech is committed to advancing therapeutic solutions that have the potential to make a significant impact in the field of immunology. Their research and development efforts aim to provide effective treatments for conditions such as pancreatic cancer, with recent authorizations and enrollments in clinical studies demonstrating their dedication to finding innovative solutions for patients in need.
Generated from the website